A historic breakthrough has been achieved in the global treatment of pancreatic cancer.

The innovative drug Daraxonrasib, developed by RedMed, has demonstrated in its latest Phase III clinical trial that it can extend the median overall survival of advanced pancreatic cancer patients to 13.2 months. This is nearly double the 6.7 months seen with traditional chemotherapy, representing a significant 60% reduction in the risk of death.

These results were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, earning a standing ovation from leading experts and heralding a major transformation in the standard of care for this challenging "king of cancers."

Beyond significantly extending survival, Daraxonrasib also outperformed chemotherapy in pain relief and quality-of-life improvements, with a lower incidence of side effects and a discontinuation rate of just 1.2%. The therapy has received a Priority Review voucher from the FDA, which is expected to accelerate its availability to patients worldwide. The market and investors are highly attentive to its broad-spectrum potential, with future prospects for expansion into other RAS-driven cancers.

This breakthrough not only advances the treatment standard for pancreatic cancer but also offers a new direction for cancer drug development. The sustained inhibition of active RAS signaling pathways has proven to be a viable strategy for treating advanced tumors. The relevant clinical data has been submitted to regulatory authorities, with follow-up trials progressing concurrently. Investors should monitor RedMed's subsequent product pipeline and global market expansion.

Triple-Complex "Molecular Glue" Locks Down Cancer Cells

The innovative mechanism of Daraxonrasib employs a "molecular glue" strategy to precisely inhibit the core driver of cancer cells—the RAS signaling pathway. Over 90% of pancreatic cancer patients have mutations in RAS genes like KRAS. The RAS protein's smooth surface, lacking traditional binding sites, had long been considered "undruggable."

Daraxonrasib achieves a breakthrough with its triple-complex inhibition mechanism. After oral administration, the drug first binds to the Cyclophilin A (CypA) protein to form a binary complex.

This complex specifically recognizes and binds to RAS(ON) proteins in their active state—molecules actively transmitting oncogenic signals.

The three components combine to form a stable ternary complex, acting like a "lock" to block RAS from sending downstream cancer-causing signals, thereby inhibiting tumor cell proliferation and metastasis.

This mechanism is inherently broad-spectrum, covering wild-type KRAS/NRAS/HRAS and various mutant subtypes like G12, G13, and Q61. It is applicable to the vast majority of advanced pancreatic cancer patients and other RAS-driven tumors.

Survival Doubled, Death Risk Slashed by 60%

Data from NEJM, the ASCO Annual Meeting, and official sources show that Daraxonrasib demonstrated significant efficacy in the Phase III RASolute 302 global multicenter randomized controlled trial.

The trial involved 500 patients with previously treated metastatic pancreatic cancer, 91.8% of whom had RAS G12 mutations.

For overall survival (OS), the Daraxonrasib group achieved a median OS of 13.2 months versus 6.7 months for the chemotherapy group, with a hazard ratio (HR) of 0.40.

For progression-free survival (PFS), the Daraxonrasib group had a median PFS of 7.2 months compared to 3.6 months for the chemotherapy group, with an HR of 0.49.

The objective response rate (ORR) was 31.6% in the Daraxonrasib group versus 11.2% in the chemotherapy group.

The Daraxonrasib group showed a 60% reduction in the risk of death (HR=0.40).

Daraxonrasib significantly delayed pain worsening (9.2 months vs. 5.7 months) and extended the time to quality-of-life deterioration (3.8 months vs. 2.6 months), with HRs of 0.51 and 0.60, respectively.

Manageable Side Effects with Far Lower Discontinuation Rate Than Chemo

Regarding safety, all patients in the Daraxonrasib group experienced treatment-emergent adverse events, primarily mild rash and gastrointestinal reactions.

The incidence of adverse events in the chemotherapy group was 97.7%, including fatigue and anemia.

Daraxonrasib had a lower incidence of Grade 3 or higher side effects (43.6%) compared to chemotherapy (57.5%). Its discontinuation rate was only 1.2%, far below the 11.2% in the chemotherapy group. Most side effects were manageable through dose adjustments or standard medications, with no unexpected safety risks identified.

New Standard Drives Industry Advancement, Broad-Spectrum Potential Offers Growth

Daraxonrasib has received an FDA Priority Review voucher, which is expected to expedite its path to market.

The industry widely anticipates that this drug could become the new standard of care for previously treated metastatic pancreatic cancer. Its broad-spectrum applicability and innovative mechanism hold promise for expansion into other RAS-driven tumors, opening a wider market opportunity. RedMed's follow-up product pipeline and global market expansion are key areas for investor focus.

The clinical breakthrough of Daraxonrasib marks a new phase in human anti-cancer drug development. The sustained inhibition of active RAS signaling pathways offers hope for patients with pancreatic cancer, doubling survival and drastically reducing the risk of death.

With regulatory acceleration and the progression of follow-up trials, RedMed and the related industry chain are poised for a new wave of growth. Investors should monitor therapy implementation, expansion of indications, and global market dynamics.